Description

VALSABROOK 160 MG

Indications

VALSABROOK 160 MG is primarily indicated for the treatment of hypertension (high blood pressure) in adults. It may also be used in combination with other antihypertensive agents to achieve optimal blood pressure control. Additionally, VALSABROOK is indicated for the treatment of heart failure and to reduce the risk of cardiovascular events in patients with left ventricular dysfunction following a myocardial infarction.

Mechanism of Action

VALSABROOK contains Valsartan, an angiotensin II receptor blocker (ARB). It works by selectively blocking the action of angiotensin II, a potent vasoconstrictor that plays a significant role in regulating blood pressure. By inhibiting the binding of angiotensin II to its receptors, VALSABROOK causes vasodilation, which leads to a decrease in blood pressure. This mechanism also helps in reducing the workload on the heart, making it effective for patients with heart failure.

Pharmacological Properties

VALSABROOK is well-absorbed after oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. The bioavailability of Valsartan is approximately 23%, and its absorption is not significantly affected by food. The drug is primarily eliminated through the liver, with a half-life of about 9 hours, allowing for once-daily dosing in most patients. Valsartan is not significantly metabolized by cytochrome P450 enzymes, which minimizes the potential for drug interactions related to hepatic metabolism.

Contraindications

VALSABROOK is contraindicated in patients with a known hypersensitivity to Valsartan or any of the excipients in the formulation. It should not be used during pregnancy, particularly in the second and third trimesters, due to the risk of fetal harm. Additionally, it is contraindicated in patients with severe hepatic impairment and those with a history of angioedema related to previous treatment with an ACE inhibitor or ARB.

Side Effects

Common side effects of VALSABROOK may include dizziness, fatigue, headache, and gastrointestinal disturbances such as diarrhea or abdominal pain. More serious side effects can include hypotension, hyperkalemia (elevated potassium levels), renal impairment, and angioedema. Patients should be monitored for these adverse effects, especially during the initiation of therapy or when the dosage is increased.

Dosage and Administration

The recommended starting dose of VALSABROOK for the treatment of hypertension is 80 mg once daily, which may be increased to 160 mg once daily based on the patient’s blood pressure response. For patients with heart failure or following a myocardial infarction, the initial dose may be lower, typically starting at 40 mg once daily, with titration based on clinical response. It is important to adhere to the prescribed dosage and consult a healthcare provider before making any changes to the medication regimen.

Interactions

VALSABROOK may interact with other medications, which can affect its efficacy and safety profile. Co-administration with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of Valsartan and can lead to renal impairment in susceptible individuals. It is essential for patients to inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Patients with renal artery stenosis, a history of angioedema, or those who are volume-depleted should use VALSABROOK with caution. Regular monitoring of renal function and serum potassium levels is recommended, especially in patients with pre-existing renal impairment or those taking other medications that may affect renal function. Additionally, patients should be advised to avoid sudden discontinuation of the medication, as this may lead to rebound hypertension.

Clinical Studies

Clinical studies have demonstrated the efficacy of VALSABROOK in reducing blood pressure and improving cardiovascular outcomes. In a randomized controlled trial involving patients with hypertension, VALSABROOK was shown to significantly lower systolic and diastolic blood pressure compared to placebo. Furthermore, studies have indicated that Valsartan reduces the incidence of heart failure hospitalization and improves survival rates in patients with left ventricular dysfunction following a myocardial infarction. These findings support the use of VALSABROOK as a first-line therapy in managing hypertension and heart failure.

Conclusion

VALSABROOK 160 MG is an effective antihypertensive agent that plays a critical role in managing high blood pressure and heart failure. Its mechanism of action as an angiotensin II receptor blocker allows for significant cardiovascular benefits, making it a valuable option in clinical practice. As with any medication, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. Regular follow-up with healthcare providers is crucial to ensure optimal therapeutic outcomes and patient safety.